Medicus Pharma Ltd (MDCX)

$0.51 +0.01 (1.80%)
Market Cap 12.72M
Revenue (ttm) 0.00
Net Income (ttm) -11.16M
EPS (ttm) N/A
PE Ratio 0.00
Forward PE N/A
Profit Margin 0.00%
Debt to Equity Ratio 0.00
Volume 1,039,500
Avg Vol 4,510,468
Day's Range N/A - N/A
Shares Out 25.55M
Stochastic %K 45%
Beta -1.58
Analysts Strong Sell
Price Target $17.67

Company Profile

Medicus Pharma Ltd., a biotech/life sciences company, focuses on developing clinical development programs of therapeutic assets in the United States. It is developing SKNJCT-003, which is in Phase 2 study for the treatment of basal cell carcinoma of the skin. Medicus Pharma Ltd. has a strategic collaboration with the Gorlin Syndrome Alliance to access to SKINJECT in Patients with Gorlin Syndrome. The company was formerly known as Interactive Capital Partners Corporation and changed its name to M...

Industry: Drug Manufacturers - General
Sector: Healthcare
Phone: 610 540 7515
Address:
300 Conshohocken State Road, Suite 200, Conshohocken, United States
neverknew
neverknew Mar. 20 at 9:06 PM
$MDCX
0 · Reply
iLiealot
iLiealot Mar. 20 at 3:48 PM
$MDCX
0 · Reply
biotrade123
biotrade123 Mar. 20 at 3:16 PM
$MDCX dripping down slowly?
0 · Reply
neverknew
neverknew Mar. 20 at 11:10 AM
$MDCX
0 · Reply
razorsedge4343
razorsedge4343 Mar. 20 at 3:23 AM
$MDCX Anyone bullish here should look at the sub $0.50 share price, the 12 million dollar market cap, then look in the mirror and realize they are lying to themselves pretending this pig will ever fly.
0 · Reply
neverknew
neverknew Mar. 20 at 2:52 AM
$MDCX
0 · Reply
GABBYGIRL
GABBYGIRL Mar. 19 at 5:58 PM
$MDCX I expect we will have a pr on this soon!
1 · Reply
juanpa9210
juanpa9210 Mar. 19 at 3:50 PM
$MDCX well...
1 · Reply
biotrade123
biotrade123 Mar. 19 at 3:07 PM
$MDCX dead board? despite a significant event ongoing now?
0 · Reply
GABBYGIRL
GABBYGIRL Mar. 19 at 2:01 PM
$MDCX Take note, the discussions begin at 11 am today! https://dilution.news/79ce047e22f11f7847dbae7efa24ac55
1 · Reply
Latest News on MDCX
Medicus Pharma To Discuss Positive Skinject(R) Phase 2 Topline Results In Fireside Chat Hosted By Brookline Capital Markets Biotechnology Equity Research Analyst

Mar 18, 2026, 7:30 AM EDT - 3 days ago

Medicus Pharma To Discuss Positive Skinject(R) Phase 2 Topline Results In Fireside Chat Hosted By Brookline Capital Markets Biotechnology Equity Research Analyst

MDCX

Medicus Pharma Announces SkinJect® Phase 2 Principal Investigator and Key Opinion Leader (KOL), Babar K. Rao MD, FAAD, to Provide Clinical Interpretation of Positive Data During Business Update Webcast on March 26

Mar 16, 2026, 7:30 AM EDT - 5 days ago

Medicus Pharma Announces SkinJect® Phase 2 Principal Investigator and Key Opinion Leader (KOL), Babar K. Rao MD, FAAD, to Provide Clinical Interpretation of Positive Data During Business Update Webcast on March 26

MDCX

Medicus Pharma Ltd. To Participate In The Longwood Miami CEO Forum

Mar 10, 2026, 7:30 AM EDT - 11 days ago

Medicus Pharma Ltd. To Participate In The Longwood Miami CEO Forum

MDCX

Medicus Pharma Provides Interpretation of Positive Phase 2 SkinJect™ Dataset

Mar 9, 2026, 7:30 AM EDT - 12 days ago

Medicus Pharma Provides Interpretation of Positive Phase 2 SkinJect™ Dataset

MDCX

Medicus Pharma Stock Swings After Skin Cancer Treatment Results

Mar 5, 2026, 9:13 AM EST - 16 days ago

Medicus Pharma Stock Swings After Skin Cancer Treatment Results

MDCX

Medicus Pharma Reports Positive Phase 2 SKNJCT-003 Topline Data Observing 73% Clinical Clearance and 40% Histological Clearance (CR) at Day 57 in 200μg Cohort

Mar 5, 2026, 7:30 AM EST - 16 days ago

Medicus Pharma Reports Positive Phase 2 SKNJCT-003 Topline Data Observing 73% Clinical Clearance and 40% Histological Clearance (CR) at Day 57 in 200μg Cohort

MDCX

Medicus Pharma To Participate in the 38th Annual Roth Conference

Mar 3, 2026, 7:30 AM EST - 18 days ago

Medicus Pharma To Participate in the 38th Annual Roth Conference

MDCX

Medicus Pharma on Bloomberg World

Feb 12, 2026, 7:30 AM EST - 5 weeks ago

Medicus Pharma on Bloomberg World

MDCX

Medicus Pharma Receives FDA “Study May Proceed” Clearance For Teverelix® Phase 2b Study in Advanced Prostate Cancer Patients with High Cardiovascular Risk

Feb 10, 2026, 7:30 AM EST - 5 weeks ago

Medicus Pharma Receives FDA “Study May Proceed” Clearance For Teverelix® Phase 2b Study in Advanced Prostate Cancer Patients with High Cardiovascular Risk

MDCX

Medicus Pharma Marks Nasdaq Anniversary With Opening Bell Ceremony

Jan 23, 2026, 7:30 AM EST - 2 months ago

Medicus Pharma Marks Nasdaq Anniversary With Opening Bell Ceremony

MDCX

Medicus Pharma Ltd. Announces Amendment to LifeArc License Improving Teverelix® Long-Term Economic and Development Profile

Jan 22, 2026, 7:30 AM EST - 2 months ago

Medicus Pharma Ltd. Announces Amendment to LifeArc License Improving Teverelix® Long-Term Economic and Development Profile

MDCX

Medicus Pharma Ltd. Celebrates One Year on Nasdaq with Opening Bell Ceremony on January 22, 2026

Jan 20, 2026, 7:30 AM EST - 2 months ago

Medicus Pharma Ltd. Celebrates One Year on Nasdaq with Opening Bell Ceremony on January 22, 2026

MDCX

Medicus Pharma Ltd. Studies Demonstrate Long-Acting Therapeutic Approach with Stable Bone Turnover in Women

Jan 12, 2026, 7:30 AM EST - 2 months ago

Medicus Pharma Ltd. Studies Demonstrate Long-Acting Therapeutic Approach with Stable Bone Turnover in Women

MDCX

Medicus Pharma Ltd. to Present at Biotech Showcase 2026 as SkinJect Phase 2 Clinical Data Approaches Readout and Partnering Readiness Accelerates

Jan 5, 2026, 7:30 AM EST - 2 months ago

Medicus Pharma Ltd. to Present at Biotech Showcase 2026 as SkinJect Phase 2 Clinical Data Approaches Readout and Partnering Readiness Accelerates

MDCX

Medicus Pharma Ltd. Announces Engagement With Reliant AI to Develop Artificial Intelligence (AI) Driven Clinical Data Analytics Platform

Dec 22, 2025, 7:30 AM EST - 3 months ago

Medicus Pharma Ltd. Announces Engagement With Reliant AI to Develop Artificial Intelligence (AI) Driven Clinical Data Analytics Platform

MDCX

Medicus Pharma Ltd. Completes Enrolment of Ninety (90) Patients for Phase 2 Clinical Study (SKNJCT-003) to Non-Invasively Treat Basal Cell Carcinoma (BCC) of the Skin

Dec 15, 2025, 7:30 AM EST - 3 months ago

Medicus Pharma Ltd. Completes Enrolment of Ninety (90) Patients for Phase 2 Clinical Study (SKNJCT-003) to Non-Invasively Treat Basal Cell Carcinoma (BCC) of the Skin

MDCX

Medicus Pharma Ltd. Enters Into $5.1 Million Warrant Inducement

Dec 5, 2025, 3:20 PM EST - 3 months ago

Medicus Pharma Ltd. Enters Into $5.1 Million Warrant Inducement

MDCX

Medicus Pharma Ltd. Appoints Carolyn Bonner as Chief Financial Officer in Addition to Her Role as President

Dec 1, 2025, 8:00 AM EST - 3 months ago

Medicus Pharma Ltd. Appoints Carolyn Bonner as Chief Financial Officer in Addition to Her Role as President

MDCX

Medicus Pharma Ltd. Explore Novel Treatment Innovations that may Revolutionize Treatments for Prostate and Skin Cancers

Nov 24, 2025, 8:00 AM EST - 4 months ago

Medicus Pharma Ltd. Explore Novel Treatment Innovations that may Revolutionize Treatments for Prostate and Skin Cancers

MDCX

Medicus Pharma Ltd. Announces Filing of FDA Commissioner's National Priority Voucher Application (CNPV) for SKNJCT-003 to Non-Invasively Treat Basal Cell Carcinoma (BCC) of the Skin

Nov 17, 2025, 7:30 AM EST - 4 months ago

Medicus Pharma Ltd. Announces Filing of FDA Commissioner's National Priority Voucher Application (CNPV) for SKNJCT-003 to Non-Invasively Treat Basal Cell Carcinoma (BCC) of the Skin

MDCX

Medicus Pharma Ltd. Provides Corporate Updates and Reports Third Quarter 2025 Financial Highlights

Nov 14, 2025, 5:00 PM EST - 4 months ago

Medicus Pharma Ltd. Provides Corporate Updates and Reports Third Quarter 2025 Financial Highlights

MDCX

Medicus Pharma Ltd. Receives Full United Kingdom Regulatory and Ethical Approvals To Expand Phase 2 Clinical Study (SKNJCT-003) To Non-Invasively Treat Basal Cell Carcinoma (BCC) of the Skin

Nov 13, 2025, 7:30 AM EST - 4 months ago

Medicus Pharma Ltd. Receives Full United Kingdom Regulatory and Ethical Approvals To Expand Phase 2 Clinical Study (SKNJCT-003) To Non-Invasively Treat Basal Cell Carcinoma (BCC) of the Skin

MDCX

Medicus Pharma Ltd. Announces Collaboration with the Gorlin Syndrome Alliance to Pursue Compassionate Use Pathway for Skinject(TM) in Patients with Gorlin Syndrome

Oct 29, 2025, 7:30 AM EDT - 5 months ago

Medicus Pharma Ltd. Announces Collaboration with the Gorlin Syndrome Alliance to Pursue Compassionate Use Pathway for Skinject(TM) in Patients with Gorlin Syndrome

MDCX

Medicus Pharma Ltd. Announces Collaboration with the Gorlin Syndrome Alliance to Pursue Compassionate Use Pathway for SKINJECT™ in Patients with Gorlin Syndrome

Oct 29, 2025, 7:30 AM EDT - 5 months ago

Medicus Pharma Ltd. Announces Collaboration with the Gorlin Syndrome Alliance to Pursue Compassionate Use Pathway for SKINJECT™ in Patients with Gorlin Syndrome

MDCX

Medicus Pharma Ltd. Announces First Patient Treated in United Arab Emirates (UAE) Sknjct-004 Phase 2 Clinical Study to Non-Invasively Treat Basal Cell Carcinoma (BCC) of the Skin

Oct 22, 2025, 7:30 AM EDT - 5 months ago

Medicus Pharma Ltd. Announces First Patient Treated in United Arab Emirates (UAE) Sknjct-004 Phase 2 Clinical Study to Non-Invasively Treat Basal Cell Carcinoma (BCC) of the Skin

MDCX

The Vanderbilt Report: Medicus Pharma Ltd Built Three Separate Billion-Dollar Bets

Oct 14, 2025, 8:07 AM EDT - 5 months ago

The Vanderbilt Report: Medicus Pharma Ltd Built Three Separate Billion-Dollar Bets

MDCX

Medicus Pharma Ltd. to Present at The Maxim Growth Summit 2025

Oct 13, 2025, 7:30 AM EDT - 5 months ago

Medicus Pharma Ltd. to Present at The Maxim Growth Summit 2025

MDCX

Medicus Pharma Ltd. to Present at the Family Office Summit in Dubai, UAE

Oct 7, 2025, 7:30 AM EDT - 5 months ago

Medicus Pharma Ltd. to Present at the Family Office Summit in Dubai, UAE

MDCX

Medicus Pharma Ltd. Receives Positive Feedback From the Food and Drug Adminstration (FDA) Type C Meeting Supporting the Development of Skinject

Sep 29, 2025, 7:30 AM EDT - 6 months ago

Medicus Pharma Ltd. Receives Positive Feedback From the Food and Drug Adminstration (FDA) Type C Meeting Supporting the Development of Skinject

MDCX

Stonegate Capital Partners Initiates Coverage on Medicus Pharma Ltd. (MDCX)

Sep 24, 2025, 9:26 AM EDT - 6 months ago

Stonegate Capital Partners Initiates Coverage on Medicus Pharma Ltd. (MDCX)

MDCX

Medicus Pharma Ltd. To Present at Brookline Capital Markets

Sep 24, 2025, 7:30 AM EDT - 6 months ago

Medicus Pharma Ltd. To Present at Brookline Capital Markets

MDCX

Medicus Pharma Ltd. Announces $8.0 Million Non-Dilutive Debenture Financing

Sep 18, 2025, 7:30 AM EDT - 6 months ago

Medicus Pharma Ltd. Announces $8.0 Million Non-Dilutive Debenture Financing

MDCX

Medicus Pharma Ltd. Provides Update on United Arab Emirates (UAE) SKNJCT-004 Phase 2 Clinical Study to Non-Invasively Treat Basal Cell Carcinoma of the Skin (BCC)

Sep 8, 2025, 7:30 AM EDT - 6 months ago

Medicus Pharma Ltd. Provides Update on United Arab Emirates (UAE) SKNJCT-004 Phase 2 Clinical Study to Non-Invasively Treat Basal Cell Carcinoma of the Skin (BCC)

MDCX

Medicus Pharma Ltd. Completes Acquisition of Antev Limited

Sep 2, 2025, 7:30 AM EDT - 7 months ago

Medicus Pharma Ltd. Completes Acquisition of Antev Limited

MDCX

Medicus Pharma Ltd. Provides Update on Doxorubicin Containing Novel Microneedle Array (D-MNA) Clinical Development Program for the Treatment of Basal Cell Carcinoma (BCC) of the Skin and Reports Second Quarter 2025 Financial Highlights

Aug 21, 2025, 7:30 AM EDT - 7 months ago

Medicus Pharma Ltd. Provides Update on Doxorubicin Containing Novel Microneedle Array (D-MNA) Clinical Development Program for the Treatment of Basal Cell Carcinoma (BCC) of the Skin and Reports Second Quarter 2025 Financial Highlights

MDCX

Medicus Pharma Ltd. Announces a Memorandum of Understanding (MOU) with Helix Nanotechnologies Inc. to Develop Thermostable Infectious Disease Vaccines

Aug 4, 2025, 7:30 AM EDT - 8 months ago

Medicus Pharma Ltd. Announces a Memorandum of Understanding (MOU) with Helix Nanotechnologies Inc. to Develop Thermostable Infectious Disease Vaccines

MDCX

Medicus Pharma Ltd. Announces Voting Results Following the Annual and Special Meeting of Shareholders

Jul 23, 2025, 7:30 AM EDT - 8 months ago

Medicus Pharma Ltd. Announces Voting Results Following the Annual and Special Meeting of Shareholders

MDCX

Medicus Pharma Ltd. to Present at BTIG Virtual Biotech Conference 2025

Jul 21, 2025, 7:30 AM EDT - 8 months ago

Medicus Pharma Ltd. to Present at BTIG Virtual Biotech Conference 2025

MDCX

Medicus Pharma Ltd. Announces Submission of Type C Meeting Request to the Food and Drug Administration (FDA)

Jul 8, 2025, 7:30 AM EDT - 9 months ago

Medicus Pharma Ltd. Announces Submission of Type C Meeting Request to the Food and Drug Administration (FDA)

MDCX

Medicus Pharma Ltd Announces a Definitive Agreement to Acquire Antev Ltd. UK

Jun 30, 2025, 7:30 AM EDT - 9 months ago

Medicus Pharma Ltd Announces a Definitive Agreement to Acquire Antev Ltd. UK

MDCX

Medicus Pharma Ltd. Announces Appointment of Andrew Smith as Chief Operating Officer

Jun 23, 2025, 7:30 AM EDT - 9 months ago

Medicus Pharma Ltd. Announces Appointment of Andrew Smith as Chief Operating Officer

MDCX

Medicus Pharma Ltd. to Present at 2025 Bio International Convention

Jun 12, 2025, 7:30 AM EDT - 10 months ago

Medicus Pharma Ltd. to Present at 2025 Bio International Convention

MDCX

Medicus Pharma Ltd. Announces Submission of Product Development Plan to the Food and Drug Administration (FDA) to Treat External Squamous Cell Carcinoma (SCC) in Horses

Jun 9, 2025, 7:30 AM EDT - 10 months ago

Medicus Pharma Ltd. Announces Submission of Product Development Plan to the Food and Drug Administration (FDA) to Treat External Squamous Cell Carcinoma (SCC) in Horses

MDCX

Medicus Pharma Ltd. Announces Closing of $7.0 Million Public Offering

Jun 2, 2025, 1:40 PM EDT - 10 months ago

Medicus Pharma Ltd. Announces Closing of $7.0 Million Public Offering

MDCX

Medicus Pharma Ltd. Announces Pricing of $7.0 Million Public Offering

May 29, 2025, 8:30 PM EDT - 10 months ago

Medicus Pharma Ltd. Announces Pricing of $7.0 Million Public Offering

MDCX

Medicus Pharma Ltd Receives Study May Proceed Approval from United Arab Emirates (UAE) Department of Health (DOH) to Commence Phase 2 Clinical Study (SKNJCT-004) to Non-Invasively Treat Basal Cell Carcinoma of the Skin (BCC)

May 22, 2025, 7:30 AM EDT - 10 months ago

Medicus Pharma Ltd Receives Study May Proceed Approval from United Arab Emirates (UAE) Department of Health (DOH) to Commence Phase 2 Clinical Study (SKNJCT-004) to Non-Invasively Treat Basal Cell Carcinoma of the Skin (BCC)

MDCX

Medicus Pharma's 'Savvy' Antev Deal De-Risks Pipeline Expansion, Enhances Near-Commercial Portfolio

May 12, 2025, 2:20 PM EDT - 11 months ago

Medicus Pharma's 'Savvy' Antev Deal De-Risks Pipeline Expansion, Enhances Near-Commercial Portfolio

MDCX

Medicus Pharma Ltd. Announces a Binding Letter of Intent to Acquire Antev Ltd.

Apr 28, 2025, 7:30 AM EDT - 11 months ago

Medicus Pharma Ltd. Announces a Binding Letter of Intent to Acquire Antev Ltd.

MDCX

Medicus Pharma Provides Update on SKNJCT-003 Phase 2 Clinical Study for the Treatment of Nodular Basal Cell Carcinoma (BCC)

Apr 21, 2025, 7:30 AM EDT - 11 months ago

Medicus Pharma Provides Update on SKNJCT-003 Phase 2 Clinical Study for the Treatment of Nodular Basal Cell Carcinoma (BCC)

MDCX

Medicus Pharma Ltd. Announces Closing of $4.2 Million Regulation A Offering

Mar 10, 2025, 4:05 PM EDT - 1 year ago

Medicus Pharma Ltd. Announces Closing of $4.2 Million Regulation A Offering

MDCX

neverknew
neverknew Mar. 20 at 9:06 PM
$MDCX
0 · Reply
iLiealot
iLiealot Mar. 20 at 3:48 PM
$MDCX
0 · Reply
biotrade123
biotrade123 Mar. 20 at 3:16 PM
$MDCX dripping down slowly?
0 · Reply
neverknew
neverknew Mar. 20 at 11:10 AM
$MDCX
0 · Reply
razorsedge4343
razorsedge4343 Mar. 20 at 3:23 AM
$MDCX Anyone bullish here should look at the sub $0.50 share price, the 12 million dollar market cap, then look in the mirror and realize they are lying to themselves pretending this pig will ever fly.
0 · Reply
neverknew
neverknew Mar. 20 at 2:52 AM
$MDCX
0 · Reply
GABBYGIRL
GABBYGIRL Mar. 19 at 5:58 PM
$MDCX I expect we will have a pr on this soon!
1 · Reply
juanpa9210
juanpa9210 Mar. 19 at 3:50 PM
$MDCX well...
1 · Reply
biotrade123
biotrade123 Mar. 19 at 3:07 PM
$MDCX dead board? despite a significant event ongoing now?
0 · Reply
GABBYGIRL
GABBYGIRL Mar. 19 at 2:01 PM
$MDCX Take note, the discussions begin at 11 am today! https://dilution.news/79ce047e22f11f7847dbae7efa24ac55
1 · Reply
biotrade123
biotrade123 Mar. 19 at 12:23 PM
$MDCX 100k PM vol??
0 · Reply
juanpa9210
juanpa9210 Mar. 18 at 4:52 PM
$MDCX why it cant break .52🙈
1 · Reply
DARKP00L
DARKP00L Mar. 18 at 11:38 AM
$MDCX 07:35 on Mar. 18 2026 Medicus Pharma To Update Review Of SkinJect SKNJCT-003 Phase 2 Clinical Trial Topline Results In Fireside Chat Hosted By Brookline Capital Markets Biotechnology Equity Research Analyst #tradeideas
0 · Reply
DARKP00L
DARKP00L Mar. 18 at 11:36 AM
$MDCX 07:35 on Mar. 18 2026 Medicus Pharma To Update Review Of SkinJect SKNJCT-003 Phase 2 Clinical Trial Topline Results In Fireside Chat Hosted By Brookline Capital Markets Biotechnology Equity Research Analyst #tradeideas
0 · Reply
GABBYGIRL
GABBYGIRL Mar. 17 at 5:08 PM
$MDCX Another key time frame
0 · Reply
GABBYGIRL
GABBYGIRL Mar. 17 at 5:08 PM
$MDCX A key date is just
0 · Reply
GABBYGIRL
GABBYGIRL Mar. 17 at 4:26 PM
$MDCX If note, while mdcx is highly speculative... 1. Analysts are reporting possible massive upside potential to tune if 3000%. 2. This is a momentum play. 3. Consensus rating is "HOLD" with some saying to "Buy " 4. The release of Positive Phase 2 date on SkinJect is the real catalyst. 5. Definitely highly speculative but also very good potential for serious profits. All data thus fat has been beyond positive & encouraging.
0 · Reply
GABBYGIRL
GABBYGIRL Mar. 17 at 4:20 PM
$MDCX Anyone know when we can expect actual phase 2 data on Medicus's SkinJect???
0 · Reply
neverknew
neverknew Mar. 17 at 8:30 AM
$MDCX
0 · Reply
razorsedge4343
razorsedge4343 Mar. 16 at 6:39 PM
$MDCX @2TrustHim They are attempting to put lipstick on this pig!
0 · Reply
GABBYGIRL
GABBYGIRL Mar. 16 at 5:27 PM
$MDCX wow! It's posted for all the world to see but you can't find it!!!!!
0 · Reply
Ulfric
Ulfric Mar. 16 at 4:20 PM
$MDCX nice update, loading up here for the ride to $1+ ☕️
0 · Reply